Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab - Concepedia

Concepedia

Publication | Open Access

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab

DOI Full Paper Access

127

Citations

20

References

2018

Year

Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Satsutani, Makoto Ogata, Takayuki Miyara, Shosaku� Nomura

International Journal of Clinical Oncology

Abstract

The NLR at 2 and 4 weeks after treatment might be a useful marker for the prediction of the treatment response or disease progression in patients with advanced NSCLC receiving nivolumab.

References

	Year	Citations

Page 1